Strategic partnerships Nanomerics actively collaborates with large pharmaceutical entities (e.g., a NASDAQ company on oral products and an Asian company on nasal delivery), presenting clear outbound collaboration and licensing opportunities for partners seeking advanced nano-enabled delivery platforms.

Diversified delivery The Molecular Envelope Technology enables oral, nasal, ophthalmic, and CNS delivery, including the ability to cross the blood-brain barrier, opening sales conversations with companies targeting pain management, neuroscience, ophthalmology, and systemic delivery of hydrophobic drugs.

Lead opportunity Lead product is a nano-enabled peptide for chronic pain with potential to address opioid-related limitations, providing a compelling value proposition for pharma companies seeking safer analgesic options or adjuncts to existing pain therapies.

Awards & visibility Recognition like the King’s Award for Enterprise 2024 and active engagement with industry groups (Royal Society of Chemistry, ELRIG) enhance credibility for business development pitches to potential licensees, partners, or investors.

Global reach Past collaborations and asset sales (e.g., interest from Virpaxpharma for nasal cannabidiol spray) indicate a track record of transactional activity and international partner interest, suggesting ready pathways for in-licensing, co-development, or distribution deals.